BriaCell Provides A Corporate Update
September 12 2017 - 8:30AM
BriaCell Therapeutics Corp.
(“BriaCell” or the
“Company”) (TSXV:BCT) (OTCQB:BCTXF), an
immuno-oncology focused biotechnology company with a proprietary
vaccine technology, is to provide a Corporate Update for the
existing and potential shareholders.
Dr. Williams, BriaCell’s President & CEO will
provide an update on BriaVax™ manufacturing and the ongoing
clinical trial, and advances in BriaCell’s R&D pipeline on
Tuesday, September 19, 2017 at 4:00 PM ET.
We welcome all our shareholders and prospective
investors, partners and patients to attend the Company's corporate
update.
1) Please use the following dial-in
info.:
USA: |
|
|
|
|
+1 712 770 4222 |
Canada, Calgary: |
|
|
|
|
+1 403 910 2412 |
Canada, Montreal: |
|
|
|
|
+1 438 320 1022 |
Canada, Toronto: |
|
|
|
|
+1 647 484 1788 |
Canada, Vancouver: |
|
|
|
|
+1 604 343 3881 |
|
|
|
|
|
|
Guest Passcode: |
|
|
|
|
152467 |
|
|
|
|
|
|
The presentation will be available for download
at http://briacell.com/investor-relations/presentations/
If your area’s dial-in info is not found in the
above listing, please kindly contact:
Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
2) To join the live presentation, please
connect to the following link:
https://imeet.com/briacell/briacelltherapeautics
- At the bottom of the middle of the screen: Click on
Join using the browser
- imeet Sign In: Enter your First Name,
Last Name, and Email address
- To join the meeting: Enter your Phone Number
or manually Dial In to the meeting
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing a targeted and safe approach to
the management of cancer. BriaCell's mission is to serve late-stage
cancer patients with no available treatment options.
Immunotherapy has come to the forefront of the
fight against cancer, harnessing the body's own immune system in
recognizing and selectively destroying the cancer cells while
sparing normal ones. Immunotherapy, in addition to generally being
more targeted and less toxic than commonly used types of
chemotherapy, is also thought to be a strong type of approach aimed
at preventing cancer recurrence.
BriaVax™, the Company's lead product candidate, is
a whole-cell breast cancer vaccine genetically engineered to
release granulocyte macrophage colony-stimulating factor (GM-CSF),
a substance that activates the immune system by allowing the body
to recognize and eliminate cancerous cells by inducing
tumor-directed T cell and potentially antibody responses.
The results of two previous Phase I clinical trials
(one with the precursor cell line not genetically engineered to
produce GM-CSF and one with BriaVax™) have been encouraging in
patients with advanced breast cancer. Most notably, one patient
with metastatic breast cancer responded to BriaVax™ with
substantial reduction in tumor burden including lung and brain
metastases. The company is currently conducting a Phase I/IIa
clinical trial for BriaVax™ in patients with advanced breast cancer
whose disease has progressed following at least one prior treatment
course. This trial is listed in ClinicalTrials.gov as
NCT03066947. The trial is being conducted along with the
co-development of BriaDx™, our companion diagnostic test. The
interim data for the first 10 patients is expected by the first
quarter of 2018.
For additional information on BriaCell, please
visit our website: http://briacell.com
About the Phase I/IIa Clinical
Trial
The Phase I/IIa clinical trial is an open-label
study enrolling up to 24 late-stage breast cancer patients with
recurrent and/or metastatic disease. Patients will be administered
BriaVax™ every two weeks for the first month of treatment, then
monthly up to one year.
The primary objective of the clinical trial is to
evaluate the safety of BriaVax™ in study subjects, and the
principal secondary objective is an evaluation of the tumor size
reduction. Tumor response will be monitored every three months
during the study. The trial will also evaluate progression-free
survival (PFS) and overall survival (OS).
For additional details regarding the clinical
trial, please visit:
https://www.clinicaltrials.gov/ct2/show/NCT03066947
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact, this
news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024